Neurotoxin component treatment for spasticity

Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

1 . A method for treating spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component from a single serotype of a  botulinum  toxin, to thereby treat the spasticity, wherein the neurotoxic component administered to the patient has been purified from a  botulinum  toxin obtained by fermenting  Clostridium botulinum.    
     
     
         2 . The method of  claim 1  wherein the single  botulinum  toxin serotype, from which the neurotoxic component administered is purified, is selected from the group consisting of  botulinum  toxin types A, B, C, D, E, F and G. 
     
     
         3 . The method of  claim 2 , wherein the  botulinum  toxin is  botulinum  toxin type A. 
     
     
         4 . The method of  claim 1 , wherein between about 1 unit and about 250 units of the neurotoxic component of the  botulinum  toxin is administered. 
     
     
         5 . The method of  claim 1 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons. 
     
     
         6 . The method of  claim 1 , wherein the spasticity is a post-stroke spasticity. 
     
     
         7 . The method of  claim 1 , wherein the spasticity is secondary to a brain injury. 
     
     
         8 . The method of  claim 1 , wherein the spasticity is secondary to a spinal cord injury. 
     
     
         9 . The method of  claim 1 , wherein the neurotoxic component is administered by local administration. 
     
     
         10 . A method for treating spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a  botulinum  toxin type A to thereby treat the spasticity, wherein the neurotoxic component administered to the patient has been purified from a  botulinum  toxin obtained by fermenting a  Clostridium botulinum  bacterium. 
     
     
         11 . The method of  claim 10 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons. 
     
     
         12 . The method of  claim 10 , wherein the spasticity is a post-stroke spasticity. 
     
     
         13 . The method of  claim 10 , wherein the spasticity is secondary to a brain injury. 
     
     
         14 . The method of  claim 10 , wherein the spasticity is secondary to a spinal cord injury. 
     
     
         15 . A method for treating post-stroke spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a  botulinum  toxin type A to thereby treat the post-stroke spasticity, wherein the neurotoxic component administered to the patient has been purified from a  botulinum  toxin type A obtained by fermenting a  Clostridium botulinum  bacterium. 
     
     
         16 . The method of  claim 15 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons. 
     
     
         17 . The method of  claim 15 , wherein the neurotoxic component is administered by local administration.